Press Release: Replay : MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for sarcoma

MD Anderson and Replay announced that the FDA has issued a 'safe to proceed' for the Investigational New Drug application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for sarcoma.